In the KEYNOTE-B96 trial ( NCT05116189 ), weekly paclitaxel with bevacizumab and pembrolizumab (Keytruda; Merck) demonstrated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback